D L Chen1, C Liess1, A Poljak1, A Xu1, J Zhang1, C Thoma1, M Trenell1, B Milner1, A B Jenkins1, D J Chisholm1, D Samocha-Bonet1, J R Greenfield1. 1. Division of Diabetes and Metabolism (D.L.C., A.B.J., D.J.C., D.S.-B., J.R.G.), Garvan Institute of Medical Research and Bioanalytical Mass Spectrometry Facility (A.P.), School of Medical Sciences (A.P., D.S.-B.), Center for Healthy Brain Ageing (A.P.), and Faculty of Medicine (J.R.G.), University of New South Wales, and Department of Radiology (B.M.), and Department of Endocrinology and Diabetes Center (J.R.G.), St Vincent's Hospital, Sydney, New South Wales 2010, Australia; Philips Healthcare (C.L.), Luebeckertordamm 5, 20099 Hamburg, Germany; State Key Laboratory of Pharmaceutical Biotechnology (A.X., J.Z.), University of Hong Kong, Hong Kong; Movelab (C.T., M.T.), Newcastle University, Newcastle-upon-Tyne NE1 7RU, United Kingdom; and School of Health Science (A.B.J.), University of Wollongong, Wollongong, New South Wales 2500, Australia.
Abstract
CONTEXT: Whereas insulin resistance and obesity coexist, some obese individuals remain insulin sensitive. OBJECTIVE: We examined phenotypic and metabolic factors associated with insulin sensitivity in both muscle and liver in obese individuals. DESIGN AND PARTICIPANTS: Sixty-four nondiabetic obese adults (29 males) underwent hyperinsulinemic (15 and 80 mU/m(2) · min)-euglycemic clamps with deuterated glucose. Top tertile subjects for glucose infusion rate during the high-dose insulin clamp were assigned Musclesen and those in the lower two tertiles were assigned Muscleres. Secondarily, top tertile subjects for endogenous glucose production suppression during the low-dose insulin clamp were deemed Liversen and the remainder Liverres. MAIN OUTCOMES MEASURES: Clinical and laboratory parameters and visceral, subcutaneous, liver, and pancreatic fat were compared. RESULTS: Musclesen and Muscleres had similar body mass index and total fat (P > .16), but Musclesen had lower glycated hemoglobin (P < .001) and systolic (P = .01) and diastolic (P = .03) blood pressure (BP). Despite similar sc fat (P = 1), Musclesen had lower visceral (P < .001) and liver (P < .001) fat. Liversen had lower visceral (P < .01) and liver (P < .01) fat and C-reactive protein (P = .02) than Liverres. When subjects were grouped by both glucose infusion rate during the high-dose insulin clamp and endogenous glucose production suppression, insulin sensitivity at either muscle or liver conferred apparent protection from the adverse metabolic features that characterized subjects insulin resistant at both sites. High-density lipoprotein-cholesterol, 1-hour glucose, systolic BP, and triglycerides explained 54% of the variance in muscle insulin sensitivity. CONCLUSIONS: Obese subjects who were insulin sensitive at muscle and/or liver exhibited favorable metabolic features, including lower BP, liver and visceral adiposity. This study identifies factors associated with, and possibly contributing to, insulin sensitivity in obesity.
CONTEXT: Whereas insulin resistance and obesity coexist, some obese individuals remain insulin sensitive. OBJECTIVE: We examined phenotypic and metabolic factors associated with insulin sensitivity in both muscle and liver in obese individuals. DESIGN AND PARTICIPANTS: Sixty-four nondiabetic obese adults (29 males) underwent hyperinsulinemic (15 and 80 mU/m(2) · min)-euglycemic clamps with deuterated glucose. Top tertile subjects for glucose infusion rate during the high-dose insulin clamp were assigned Musclesen and those in the lower two tertiles were assigned Muscleres. Secondarily, top tertile subjects for endogenous glucose production suppression during the low-dose insulin clamp were deemed Liversen and the remainder Liverres. MAIN OUTCOMES MEASURES: Clinical and laboratory parameters and visceral, subcutaneous, liver, and pancreatic fat were compared. RESULTS: Musclesen and Muscleres had similar body mass index and total fat (P > .16), but Musclesen had lower glycated hemoglobin (P < .001) and systolic (P = .01) and diastolic (P = .03) blood pressure (BP). Despite similar sc fat (P = 1), Musclesen had lower visceral (P < .001) and liver (P < .001) fat. Liversen had lower visceral (P < .01) and liver (P < .01) fat and C-reactive protein (P = .02) than Liverres. When subjects were grouped by both glucose infusion rate during the high-dose insulin clamp and endogenous glucose production suppression, insulin sensitivity at either muscle or liver conferred apparent protection from the adverse metabolic features that characterized subjects insulin resistant at both sites. High-density lipoprotein-cholesterol, 1-hour glucose, systolic BP, and triglycerides explained 54% of the variance in muscle insulin sensitivity. CONCLUSIONS: Obese subjects who were insulin sensitive at muscle and/or liver exhibited favorable metabolic features, including lower BP, liver and visceral adiposity. This study identifies factors associated with, and possibly contributing to, insulin sensitivity in obesity.
Authors: Roland Stocker; David E James; Daniel J Fazakerley; Rima Chaudhuri; Pengyi Yang; Ghassan J Maghzal; Kristen C Thomas; James R Krycer; Sean J Humphrey; Benjamin L Parker; Kelsey H Fisher-Wellman; Christopher C Meoli; Nolan J Hoffman; Ciana Diskin; James G Burchfield; Mark J Cowley; Warren Kaplan; Zora Modrusan; Ganesh Kolumam; Jean Yh Yang; Daniel L Chen; Dorit Samocha-Bonet; Jerry R Greenfield; Kyle L Hoehn Journal: Elife Date: 2018-02-06 Impact factor: 8.140
Authors: Jibran A Wali; Yen Chin Koay; Jason Chami; Courtney Wood; Leo Corcilius; Richard J Payne; Roman N Rodionov; Andreas L Birkenfeld; Dorit Samocha-Bonet; Stephen J Simpson; John F O'Sullivan Journal: Am J Physiol Endocrinol Metab Date: 2020-07-14 Impact factor: 4.310
Authors: Alexandre A da Silva; Jussara M do Carmo; Xuan Li; Zhen Wang; Alan J Mouton; John E Hall Journal: Can J Cardiol Date: 2020-02-12 Impact factor: 5.223
Authors: Daniel J Fazakerley; James R Krycer; Alison L Kearney; Samantha L Hocking; David E James Journal: J Lipid Res Date: 2018-07-27 Impact factor: 5.922